Navigation Links
Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
Date:12/12/2011

He also serves as co-director of the RNA Therapeutics Institute at the University of Massachusetts Medical School.  

Forward-Looking Statements

This press release includes forward-looking statements that are subject to risks, uncertainties and other factors. These risks and uncertainties could cause actual results to differ materially from those referred to in the forward-looking statements. All forward-looking statements are based on information currently available to Silence Therapeutics and Silence Therapeutics assumes no obligation to update any such forward-looking statements.

For further information, please contact:


    Silence Therapeutics
    Thomas Christély/Max Herrmann
    +49-30-9489-2800 / +44(0)20-7491-6520
    t.christely@silence-therapeutics.com
    m.herrmann@silence-therapeutics.com

 

    Singer Capital Markets
    Shaun Dobson/Claes Spång
    +44(0)20-32057500
    shaun.dobson@singercm.com
    claes.spang@singercm.com

 

    M:Communications (Europe)
    Peter Laing / Emma Thompson
    +44(0)20-7920-2345 / +44(0)20-7920-2342
    healthcare@mcomgroup.com


'/>"/>
SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
2. Silence Therapeutics Provides Corporate and Development Update
3. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
4. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
5. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
6. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
7. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
8. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
9. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
10. Silence Therapeutics Appoints New Vice President of Research
11. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... laureate Herbert Kroemer famously observed, referring to the ... where layers of different materials meet. In today,s ... of metal oxides are becoming increasingly prominent, with ... superconductors, ferroelectrics and multiferroics. Realizing the vast potential ...
(Date:1/15/2014)... January 15, 2014 Look inside the ... items for the lab, from fluid handling to instruments ... to ship when you order. , Preferred Solutions ... , from the L/S® model for precise flow control ...
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains ... these latent viruses is the Epstein Barr Virus (EBV), and ... (RA) is a chronic inflammatory disease that destroys the body’s ... RA patients have high concentrations of EBV DNA in their ...
Breaking Biology Technology:A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... ... therapy. Two years after endovascular treatment, 88 percent of women avoided amputation compared to ... ... are at risk of lower-leg amputation fare even better than men when they have minimally ...
... divas of the nanoworld. In possession of alluring properties, ... cousins. On the plus side, they can withstand ... Yoke Khin Yap, an associate professor of physics at ... in a barbecue at half of those temperatures," he ...
... , , , , , SAN ... ), a biopharmaceutical company focused on developing and commercializing novel ... Chief Executive Officer, is scheduled to present at the 28th ... 2009 at the Westin St. Francis Hotel in San Francisco, ...
Cached Biology Technology:Women More Likely Than Men to Avoid Amputation After Minimally Invasive Therapy for Blocked Leg Arteries 2Women More Likely Than Men to Avoid Amputation After Minimally Invasive Therapy for Blocked Leg Arteries 3Harnessing the divas of the nanoworld 2NeurogesX to Present at J.P. Morgan Health Care Conference 2NeurogesX to Present at J.P. Morgan Health Care Conference 3
(Date:7/9/2014)... can alleviate the symptoms of Alzheimer,s disease, ... and effectively scavenge amyloid beta peptide in ... reduced and eliminated Aβ deposition in an ... significantly improved behavioral and cognitive impairment. Dr. ... Hospital of China Medical University, China immunized ...
(Date:7/9/2014)... numerous inhabitants of the sea: tiny haptophytes of the ... naked eye, when they are in bloom in spring, ... visible on satellite images. "Together with other phytoplankton, ... the global photosynthesis output," states Prof. Dr. Georg Pohnert ... process the greenhouse gas carbon dioxide CO2 ...
(Date:7/8/2014)... future health of the world,s coral reefs and the ... the ability of one tiny symbiotic sea creature to ... algae it cooperates with. , In the first study ... discovered that coralstiny reef-forming animals that live symbiotically with ... heat stress, called "bleaching," when they keep large energy ...
Breaking Biology News(10 mins):Short circuit in the food web 2For corals adapting to climate change, it's survival of the fattest -- and most flexible 2For corals adapting to climate change, it's survival of the fattest -- and most flexible 3For corals adapting to climate change, it's survival of the fattest -- and most flexible 4
... of the Spanish Foundation for Biodiversity, the Charter Provincial Council ... R+D Centre will be studying the re-stocking of the three ... of May, June and July, respectively, in three streams of ... information needed to be able to manage the species and ...
... This release is available in German . ... Germany, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to ... by the appropriate Grants Committee in Bonn. The new institutions ... half years, during which time they will receive total funding ...
... the Walter and Eliza Hall Institute in Melbourne, Australia, ... the UK,s peak academy promoting excellence in science. ... to the Royal Society in 2011, including four Australians. ... process on the basis of excellence in science. ...
Cached Biology News:A study will enable the survival and growth of the 3 development phases of the European eel 2DFG establishes 18 new research training groups 2DFG establishes 18 new research training groups 3DFG establishes 18 new research training groups 4DFG establishes 18 new research training groups 5DFG establishes 18 new research training groups 6DFG establishes 18 new research training groups 7DFG establishes 18 new research training groups 8DFG establishes 18 new research training groups 9DFG establishes 18 new research training groups 10Top Australian malaria researcher elected Fellow of the Royal Society 2Top Australian malaria researcher elected Fellow of the Royal Society 3
... the needs of the biopharmaceutical ... supports fast cell growth rates ... maintaining high cell viability and ... the Baculovirus Expression Vector System ...
Mol wt: average mol wt12,360.96 Da by calculation...
A set of five proteins which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
Originally developed for the culture of Drosophila; suitable for culture of other dipteran cell lines. Powder, Insect cell culture tested...
Biology Products: